NEWS
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
Cosmos Health (NASDAQ:COSM) has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders. The product utilizes advanced biopolymeric grids from natural ingredients to encapsulate bioactive molecules, enhancing drug efficacy at targeted sites. Current efforts focus on improving physicochemical properties and evaluating gut microflora impact through in vitro studies and simulations.
The global gastrointestinal therapeutics market, valued at $37.6 billion in 2022, is projected to grow at a 3.3% CAGR from 2023 to 2030. This growth is driven by the increasing prevalence of GI disorders and rising demand for effective treatments. CCDL24 builds on the success of CCX0722, leveraging biocompatible hydrogels from natural sources to create biopolymeric matrices for gastrointestinal health.
The global gastrointestinal therapeutics market, valued at $37.6 billion in 2022, is projected to grow at a 3.3% CAGR from 2023 to 2030. This growth is driven by the increasing prevalence of GI disorders and rising demand for effective treatments. CCDL24 builds on the success of CCX0722, leveraging biocompatible hydrogels from natural sources to create biopolymeric matrices for gastrointestinal health.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2334Followers
106Following
24KVisitors
Follow